Abstracts tagged "Epidemiologic methods"

Abstract Number: 1972 • 2015 ACR/ARHP Annual Meeting
Cardiovascular and Cerebrovascular Disease and Social Deprivation in Patients with Giant Cell Arteritis
Joanna Robson¹, Amit Kiran², Andrew Hutchings³, Joseph Maskell⁴, Nigel K Arden⁵, Willie Hamilton⁶, Bhaskar Dasgupta^7,8 and Raashid Luqmani⁹, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, University of Oxford, Oxford, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom, ³Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom, ⁴Faculty of Medicine, University of Southampton, Southampton, United Kingdom, ⁵Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom, ⁶Primary Care, University of Exeter, Exeter, United Kingdom, ⁷Southend University Hospital, Southend, United Kingdom, ⁸Rheumatology, Southend University Hospital, Essex, United Kingdom, ⁹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis in the UK, with an incidence of 2.2 cases per 10,000 person-years. Cerebrovascular…
Abstract Number: 2466 • 2014 ACR/ARHP Annual Meeting
Increased Risk of Rheumatoid Arthritis (RA) Among Shared Epitope-Negative (SE-) Mothers with Shared Epitope-Positive (SE+) Children
Giovanna Cruz¹, Lindsey A. Criswell², Xiaorong Shao³, Hong L. Quach¹, Janelle Noble⁴, Nikolaos Patsopoulos⁵, Michael Busch⁶ and Lisa F. Barcellos¹, ¹Epidemiology, University of California, Berkeley, Berkeley, CA, ²Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ³Genetic Epidemiology and Genomics Lab, Division of Epidemiology, University of California, Berkeley, Berkeley, CA, ⁴Children's Hospital Oakland Research Institute (CHORI), Oakland, CA, ⁵Division of Genetics, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ⁶Blood Systems Research Institute, San Francisco, CA
Background/Purpose RA (RA [MIM 180300]) disproportionately affects women of reproductive age, implicating pregnancy-related factors. Fetal microchimerism (FMC), or the persistence of a small population of…
Abstract Number: 822 • 2014 ACR/ARHP Annual Meeting
Meloxicam and Risk of Myocardial Infarction: A Population-Based Cohort Study
Deepan Dalal¹, Maureen Dubreuil^2,3, Yuqing Zhang⁴, Christine Peloquin⁵, Tuhina Neogi⁴, Hyon K. Choi² and David T. Felson⁶, ¹Rheumatology, Boston Medical Center, Boston, MA, ²Rheumatology, Boston University School of Medicine, Boston, MA, ³Rheumatology, VA Boston Healthcare System, Jamaica Plain, MA, ⁴Boston University School of Medicine, Boston, MA, ⁵Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA, ⁶Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Certain non-steroidal anti-inflammatory drugs (NSAIDs) have been associated with an increased risk of myocardial infarction (MI). MI risk for different NSAIDs varies largely because…
Abstract Number: 2418 • 2014 ACR/ARHP Annual Meeting
Treatment Pattern and Direct Cost of Biologics for Rheumatoid Arthritis Patients: A Real-World Analysis of Nationwide Japanese Claims Data
Naonobu Sugiyama M.D., Ph.D¹, Tatsunori Murata, M.S.², Yosuke Morishima³, Yuri Fukuma⁴, Yoshiyuki Shibasaki⁴ and Lisa Marshall⁵, ¹Medical Affairs, Pfizer Japan Inc. RA & Inflammation Area Medical Affairs Department, Tokyo, Japan, ²Health Economics Research Group, CRECON Research and Consulting Inc., Tokyo, Japan, ³RA & Inflammation Area Medical Affairs Department, Pfizer Japan Inc. RA & Inflammation Area Medical Affairs Department, Tokyo, Japan, ⁴Pfizer Japan Inc. RA & Inflammation Area Medical Affairs Department, Tokyo, Japan, ⁵Inflammation Immunology Disease Group, Pfizer Inc. Inflammation Immunology Disease Group, Collegeville, PA
Background/Purpose Biologics such as etanercept (ETN), adalimumab (ADA), infliximab (IFX) and tocilizumab (TCZ) have led dramatic improvement in the treatment of rheumatoid arthritis (RA), but…
Abstract Number: 791 • 2014 ACR/ARHP Annual Meeting
Comparison of Clinical Manifestations in Different Histological Subsets of Biopsy-Proven Giant Cell Arteritis
Luigi Boiardi¹, Francesco Muratore¹, Alberto Cavazza², Giovanna Restuccia³, Pierluigi Macchioni¹, Giuseppe Germanò¹, Nicolò Pipitone¹, Gianluigi Bajocchi⁴ and Carlo Salvarani¹, ¹Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ²Pathology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ³Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁴Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Japan
Background/Purpose: Temporal artery biopsy (TAB) showing transmural inflammation is considered the gold standard for the diagnosis of giant cell arteritis (GCA). In some cases of…
Abstract Number: 2071 • 2014 ACR/ARHP Annual Meeting
Chronic Widespread Pain Versus Multi-Site Pain: Does the Distribution Matter?
Marcus Beasley and Gary J. Macfarlane, Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom
Background/Purpose: The ACR 1990 diagnostic criteria for fibromyalgia includes a definition for chronic widespread pain (CWP) that depends on a particular distribution of pain sites.…
Abstract Number: 786 • 2014 ACR/ARHP Annual Meeting
The Incidence and Mortality Rates of Giant Cell Arteritis in Southern Norway Are Lower Than Previous Reported
Andreas P. Diamantopoulos¹, Glenn Haugeberg¹, Lisa Amundsen², Elisabeth Wigaard¹, Dag Magnar Soldal¹ and Geirmund Myklebust¹, ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Hospital of Southern Norway Trust, Kristiansand, Norway
The Incidence and Mortality rates of Giant Cell Arteritis in Southern Norway are lower than Previous ReportedBackground/Purpose Giant cell arteritis (GCA) is the most common…
Abstract Number: 2067 • 2014 ACR/ARHP Annual Meeting
Understanding the Factors Influencing Time to Diagnosis in Fibromyalgia
Howard Amital¹, Yaeli Bar-On², Varda Shalev³, Dahlia Weitzman³ and Gabriel Chodick⁴, ¹Department of Medicine B, Center for Autoimmune Diseases, Sheba Medical Center, Tel-hashomer, Israel, ²Department of Medicine E,, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, ³Medical Informatics, Maccabi Healthcare Services, Tel Aviv, Tel-Aviv, Israel, ⁴Medical Informatics, Healthcare Services, Tel Aviv, Tel-Aviv, Israel
Background/Purpose - Fibromyalgia (FM) is a chronic debilitating disorder considered to be part of a spectrum of central sensitization syndromes. The diagnosis of FM is…
Abstract Number: 623 • 2014 ACR/ARHP Annual Meeting
Epigenetic Studies in Maternally Versus Paternally Transmitted Psoriatic Disease
Darren D. O'Rielly¹, Remy Pollock², Yuhua Zhang³, Nayef Al Ghanim¹, Sean Hamilton¹, Dafna D. Gladman², Vinod Chandran², Rose Ardern¹, Guangju Zhai³ and Proton Rahman¹, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Discipline of Genetics, Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada
Background/Purpose: Epidemiological studies have noted excess paternal transmission in psoriasis and psoriatic arthritis. To date, there has been no molecular explanation to account for this…
Abstract Number: 2039 • 2014 ACR/ARHP Annual Meeting
Among Persons Assayed with Lower Serum Interleukin-1 Beta (IL-1β) Levels, Serum Androstenedione (Δ4A) and Testosterone (T) Were Significantly Lower in a Community-Based Cohort of Rheumatoid Arthritis Multi-Years before Clinical Onset (Pre-RA) Than in Non-RA Matched Control (CN) Subjects
Alfonse T. Masi, Azeem A. Rehman and Jean C. Aldag, Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL
Background/Purpose: Dysregulations in androgenic-anabolic (A-A) steroids and cytokines are recognized in RA and pre-RA subjects (Rheum Dis Clin N Am 2005; 31: 131-60). However, deviations…
Abstract Number: 480 • 2014 ACR/ARHP Annual Meeting
Serious Infection Risk By Treatments and Types in Patients with RA
Kaleb Michaud^1,2, Sofia Pedro¹, Andre Kalil³, Ted R. Mikuls⁴ and Frederick Wolfe¹, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ³Infectious Diseases, University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Recent studies provide conflicting results on the impact of DMARDs on the risk of serious infections for patients with RA. We examined these infection…
Abstract Number: 2038 • 2014 ACR/ARHP Annual Meeting
Respiratory Cause Mortality Was Significantly Predicted By Incident Rheumatoid Arthritis (RA) and Higher Pre-RA Levels (0.50+ SD) of Soluble Interleukin-2 Receptor Alpha (sIL-2Rá): Results of a 21-Year Community-Based Cohort Survival Analysis
Alfonse T. Masi¹, Azeem Rehman¹, Huaping Wang¹ and Jean Aldag², ¹Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, ²Medicine, University of Illinois College of Medicince at Peoria, retired, Peoria, IL
Background/Purpose: Interstitial lung disease (ILD) mortality is reported to be increased in RA (Bongartz T et al. A&R 2010; 62: 1583-91). However, non-malignant respiratory mortality…
Abstract Number: 358 • 2014 ACR/ARHP Annual Meeting
Parity and Severity of ACPA-Positive/Negative Rheumatoid Arthritis. Results from the Swedish EIRA Study
Mitra Pikwer¹, Cecilia Orellana², Henrik Källberg², Andreas Pikwer³, Carl Turesson⁴, Lars Klareskog⁵, Lars Alfredsson^6,7, Saedis Saevarsdottir⁸ and Camilla Bengtsson⁹, ¹Rheumatology Unit, Mälarhospital, Institute of Environmental Medicine, Eskilstuna, Sweden, ²Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Centre of Clinical Research Sörmland, Eskilstuna, Sweden, ⁴Rheumatology, Department of Clinical Sciences, Malmö, Sweden, ⁵Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska institutet, Stockholm, Sweden, ⁶Institute of Environmental Medicine, Stockholm, Sweden, ⁷Centre of Occupational and Environmental Medicine, Stockholm, Sweden, ⁸Institute of Environmental Medicine, Karolinska Institutet,, Stockholm, Sweden, ⁹The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose Female sex and older age are known risk factors for rheumatoid arthritis (RA). The disease is however heterogeneous, and a common division occurs between…
Abstract Number: 2022 • 2014 ACR/ARHP Annual Meeting
First Nations Persons Have an Increased Risk of Developing Rheumatoid Arthritis with an Early Onset Age but Are Seen Less Frequently By Rheumatologists: A Population Based Study
Carol A. Hitchon¹, Sazzadul Khan², Brenda Elias³, Hani S. El-Gabalawy⁴, Alan Katz⁵ and Christine A. Peschken¹, ¹Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ²Manitoba Centre for Health Policy and Research, University of Manitoba, Winnipeg, MB, Canada, ³Department of Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ⁴Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada
Background/Purpose High global prevalence rates of rheumatoid arthritis (RA) have been reported in First Nations (FN). For our regional population of 1.2 million, health care…
Abstract Number: 234 • 2014 ACR/ARHP Annual Meeting
The Decrease in Prescription of Anti-Osteoporotic Drugs Has No Impact on Hip Fracture Incidence
Karine Briot¹, Milka Maravic² and Christian Roux³, ¹Cochin Hospital, Paris Descartes University, Paris, France, ²Hopital Leopold Bellan, Paris, France, ³Paris Descartes University, Cochin Hospital, Paris, France
Background/Purpose Controversies exist about the change in hip fracture incidence among countries. In France, we previously showed that the incidence of hip fractures decreased in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].